Clinuvel gets green light

By Dylan Bushell-Embling
Wednesday, 11 June, 2008

Clinuvel Pharmaceuticals (ASX: CUV) has received ethical approval to begin Phase II testing of its solar urticaria (SU) treatment.

SU is a severe but rare disease that effects less than one per cent of the population. An SU sufferer's skin becomes badly sunburned after limited contact with the sun.

More prolonged exposure can cause red welts to appear on the skin, and can cause fainting, nausea and headaches. Symptoms last up to 24 hours.

Clinuvel hopes its new photo-receptive drug, CUV1647, can prove an effective preventative treatment for SU sufferers.

CUV1647 is expected to have a number of applications in the treatment of human diseases caused by abnormal quantities of melanin in the skin.

The trial will be conducted at Hope Hospital in Manchester in the UK.

Related News

Clinical trials facility opens in Adelaide

Pharmaceutical company IDT Australia has officially opened CMAX Adelaide, claimed to be...

AusMedtech is coming to Adelaide

Australian medical technology conference AusMedtech is coming to the Adelaide Convention and...

CSL marks centenary with $25 million fellowship program

Biotechnology company CSL observed a significant milestone on 25 April — 100 years of...

  • All content Copyright © 2016 Westwick-Farrow Pty Ltd